Humanigen’s COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without Ventilation
Humanigen Inc (NASDAQ:HGEN) has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with…
Humanigen Announces Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
Lenzilumab treatment in Black and African-American patients in the positive LIVE-AIR Phase 3 trial, having a CRP<150 mg/L, resulted in a nearly 9-fold increase in survival without ventilation
CDC data shows Black
Unusual Options Activity Insight: Humanigen
Shares of Humanigen (NASDAQ:HGEN) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $16.85.
Humanigen Stock Jumps As Lenzilumab Application Is Under Review In UK For COVID-19
The U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted for review Humanigen Inc’s (NASDAQ:HGEN) marketing application seeking approval for…
Benzinga Pro’s Top 5 Stocks To Watch For Friday, Jul. 9, 2021: GS, HGEN, TBLT, ANY, RSLS
Today's 5 Stock Ideas
Goldman Sachs (GS) - Will report Q2 earnings on Tuesday, Jul. 13 before market open. The big bank stocks have historically marked the start of the earnings season.
Humanigen
The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency
Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’, today announced it has
Credit Suisse Initiates Coverage On Humanigen with Outperform Rating, Announces Price Target of $28
Credit Suisse analyst Tiago Fauth initiates coverage on Humanigen (NASDAQ:HGEN) with a Outperform rating and announces Price Target of $28.